ESR1 and breast cancer: Collectively, we here demonstrate that BCL2 inhibitors decrease mitochondrial bioenergetics and that the targeting of glycolysis, mitochondrial metabolism and cell death signalling by a combination of BCL-2 and glycolysis inhibitors could potentially benefit both ER+ and TNBC breast cancer subtypes.